Devrim-Uçok Müge, Keskin-Ergen H Yasemin, Uçok Alp
Department of Physiology, University of Istanbul, Istanbul Medical Faculty, 34093 Capa-Istanbul, Turkey.
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1952-6. doi: 10.1016/j.pnpbp.2008.09.018. Epub 2008 Oct 1.
Deficit in P50 sensory gating has repeatedly been shown in schizophrenia. In order to determine the contribution of trait and/or state features to P50 gating deficit in schizophrenia we evaluated the P50 gating in patients with first-episode schizophrenia (FES) at acute and post-acute phases. Subject groups comprised 16 patients with FES and 24 healthy controls. Patients were tested at the acute phase of the illness and retested at the post-acute phase when their positive symptoms improved. During the testing at the acute phase five patients were neuroleptic-naive and the others were taking atypical antipsychotics which were started recently in order to control the acute excitation. Patients were receiving risperidone, olanzapine or quetiapine treatment at the post-acute phase. P50 gating was impaired in patients at the acute phase compared to controls. However, at the post-acute phase P50 gating was increased compared to the acute phase, reaching to the gating values of controls. P50 gating improvement might be emerged from atypical antipsychotic medication, although this can only be definitively determined by randomized studies including different antipsychotics.
精神分裂症患者反复出现P50感觉门控缺陷。为了确定特质和/或状态特征对精神分裂症患者P50门控缺陷的影响，我们评估了首发精神分裂症（FES）患者急性期和急性后期的P50门控。研究对象包括16例FES患者和24名健康对照者。患者在疾病急性期接受测试，并在急性后期阳性症状改善时再次进行测试。在急性期测试时，5例患者未使用过抗精神病药物，其他患者正在服用最近开始使用的非典型抗精神病药物以控制急性兴奋症状。患者在急性后期接受利培酮、奥氮平或喹硫平治疗。与对照组相比，急性期患者的P50门控受损。然而，与急性期相比，急性后期的P50门控有所增加，达到了对照组的门控值。P50门控的改善可能源于非典型抗精神病药物治疗，尽管这只能通过包括不同抗精神病药物的随机研究来最终确定。
